Madrigal Pharmaceuticals, Inc. (MDGL): Product News News

MDGL – Madrigal Pharmaceuticals MGL-3196 achieves primary endpoint in patients with biopsy-proven non-alcoholic steatohepatitis.

Key Facts Surrounding This News Item

  • MDGL had a POWR Rating of B (Buy) coming into today.
  • MDGL was -1.40% below its 10-Day Moving Average coming into today.
  • MDGL was 3.58% above its 20-Day Moving Average coming into today.
  • MDGL was 1.94% above its 50-Day Moving Average coming into today.
  • MDGL was 47.18% above its 100-Day Moving Average coming into today.
  • MDGL was 96.50% above its 200-Day Moving Average coming into today.
  • MDGL had returned +210.74% year-to-date leading up to today’s news, versus a 0.00% return from the benchmark S&P 500 during the same period.

More Info About Madrigal Pharmaceuticals, Inc. (MDGL)

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of cardiovascular, metabolic, and liver diseases. The company was founded in 2011 and is based in Fort Washington, Pennsylvania. View our full MDGL ticker page with ratings, news, and more.

MDGL at a Glance

MDGL Current POWR Rating™
Overall POWR Rating™
MDGL Current Price $129.94 2.09%
More MDGL Ratings, Data, and News

MDGL Price Reaction

The day of this event (Dec. 6, 2017)
MDGL Closing Price$87.18 88.29%
MDGL Volume3,218,600
7,316.40% from avg
Leading up to this event
MDGL 1-mo return3.50%
After this event
MDGL 1-day return43.79%
MDGL 3-day return43.55%
MDGL 5-day return42.90%

MDGL Price Chart

More Madrigal Pharmaceuticals, Inc. (MDGL) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All MDGL News
Page generated in 1.1774 seconds.